Abstract:Abstract Background: Tumor heterogeneity plays a crucial role in disease progression, metastasis and treatment response in lung adenocarcinoma (LUAD). Limited availability of multiple molecularly profiled samples from the same patients poses a challenge to validate models of tumor evolution using real-world data. We investigated genomic changes in a large cohort of patients with clinically directed DNA sequencing of multiple LUAD samples. Methods: We analyzed longitudinal genomic data from 524 patients with at least two LUAD samples sequenced with MSK-IMPACT- a targeted panel that identifies somatic mutations, copy number alterations and gene fusions in 341-505 genes. Our analysis of 1084 tumors (634 primaries [P] and 450 metastases [M]) included 189 matched P-P pairs, 99 M-M pairs and 271 P-M pairs. Pairs were required to share an identical somatic mutation to confirm relatedness. Additional criteria included: excision of primary tumor prior to excision of the metastasis in P-M pairs collected over 90 days apart and collection of M-M pairs from the same anatomic site. Intra-pulmonary metastases were removed from P-P pairs. Results: Tumor mutational burden was correlated in paired specimens from the same patient, irrespectively of P-P (R= 0.75, p<0.001; Spearman correlation), P-M (R=0.72, p<0.001) or M-M (R=0.6, p<0.001) status. Chromosomal instability, measured as the fraction of genome altered by copy number changes (FGA), was also correlated in P-P (R=0.69, p<0.001) and M-M (R=0.57, p<0.001) pairs, but tended to increase in metastases with respect to matched primaries (median 0.58 vs. 0.72, p<0.001; Wilcoxon test). In M-M pairs, changes in FGA differed by anatomic site. Liver pairs had the strongest correlation (n=17 pairs, R=0.86, p <0.01), whereas brain pairs had the weakest (n=35 pairs, R=0.085, p=0.71). Most somatic mutations were shared between paired samples (P-P: 639/1055, 60%, P-M: 1563/2877, 54%, M-M: 550/958, 57%), including those in LUAD drivers- TP53, KRAS, and EGFR. Conversely, most oncogenic copy number alterations - including CDKN2A deletions and MET amplifications - were private to one specimen (P-P: 183/276, 66%, P-M: 880/1148, 76%, M-M: 430/601, 71%), most often in the later sample (P-P: 113/183, 61%, P-M: 636/880, 72%, M-M: 212/430, 49%). Clinically targetable alterations (OncoKB Level 1) tended to be shared by tumor pairs from the same patient (93% shared vs. 6% private in P-P, p<0.01; 85% vs. 14% in P-M, p<0.01; 78% vs. 21% in M-M, p <0.01). Conclusions: In LUAD, metastatic specimens exhibit increased chromosomal instability in relation to their matched primaries. This translates into unique copy number alterations detected only in the metastasis. By contrast, driver mutations - which account for most of the clinically targetable alterations with currently approved FDA drugs - are more often shared between paired samples from the same patient. Citation Format: Brooke Mastrogiacomo, Elizabeth G. Dunne, Cameron N. Fick, John Nguyen, Jairam Hathwar, Manendra Lankadasari, Yuan Liu, Soo-Ryum Yang, Jason Chang, Walid K. Chatila, Nikolaus Schultz, David R. Jones, Francisco Sanchez-Vega. Longitudinal analyses of clinical sequencing data provide novel insights into the evolutionary dynamics of lung adenocarcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2556.

Intratumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multiregion Sequencing

Intratumor Heterogeneity (ITH) of Lung Adenocarcinomas Defined by Multiregion Whole Exome Sequencing (WES).

Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study

Identification Of Somatic Mutations In Non-Small Cell Lung Carcinomas Using Whole-Exome Sequencing

Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma

Genomic Heterogeneity of Multiple Synchronous Lung Cancer

Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing

Identification Of Genetic Mutations In Human Lung Cancer By Targeted Sequencing

Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer

Comprehensive Investigation of Mutational Features of Various Lung Adenocarcinoma Histological Subtypes among Chinese Patients.

Intratumor heterogeneity of driver mutations and TMB distribution in 30 early-stage LUAD patients with multiple lesions

Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer

Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients

Abstract 2556: Longitudinal analyses of clinical sequencing data provide novel insights into the evolutionary dynamics of lung adenocarcinoma

Identification of distinct tumor cell patterns with single-cell RNA sequencing integrating primary lung adenocarcinoma and brain metastasis tumor

Targeted Sequencing Reveals Distinct Pathogenic Variants in Chinese Patients with Lung Adenocarcinoma Brain Metastases.

Genomic heterogeneity of multiple synchronous lung cancers in Chinese population

Genetic And Epigenetic Intratumor Heterogeneity Impacts Prognosis Of Lung Adenocarcinoma

P3.16-053 Genomic Challenges for Lung Cancers with Multiple Pulmonary Sites of Involvement

Genomic and immune heterogeneity of multiple synchronous lung adenocarcinoma at different developmental stages

Targeted Deep Sequencing Helps Distinguish Independent Primary Tumors from Intrapulmonary Metastasis for Lung Cancer Diagnosis.